| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 16, 2012New Randomized Controlled Trial Results Presented At EuroPCR Demonstrate Clinical Advantages Favoring Drug-Eluting Balloons Over Uncoated Balloons and Stents
PARIS--(BUSINESS WIRE)--May. 16, 2012-- Physicians presented today at EuroPCR 2012 the results of two multicenter, randomized controlled trials, the BELLO and PACIFIER studies, each one showing...
-
May 16, 2012Randomized Controlled Trial Results Presented At EuroPCR Demonstrate Advantages Over Uncoated Angioplasty Balloons and Drug-Eluting Stents
PARIS--(BUSINESS WIRE)--May. 16, 2012-- Please replace the release with the following corrected version due to multiple revisions. The corrected release reads: MEDTRONIC IN.PACT DRUG-ELUTING...
-
May 16, 2012Closure Ends Federal Civil and Criminal Investigations of the Company
MINNEAPOLIS--(BUSINESS WIRE)--May. 16, 2012-- Medtronic, Inc. (NYSE: MDT) today announced it has been notified by the U.S. Department of Justice (DOJ) and the Office of the United States Attorney...
-
May 15, 2012
MINNEAPOLIS--(BUSINESS WIRE)--May. 15, 2012-- Medtronic (NYSE: MDT) will host an institutional investor and analyst meeting on Friday, June 1, 2012, in New York City from 9:00 a.m. to...
-
May 15, 2012With Latest Certifications, Company’s Flagship DES Has Broadest Range of Approved Indications in Europe; Study Findings Presented at EuroPCR
PARIS--(BUSINESS WIRE)--May. 15, 2012-- As EuroPCR 2012 gets under way today, Medtronic, Inc. (NYSE: MDT) announced that the Resolute Integrity Coronary Stent System has received European...